Japanese Generic Drug Maker Towa Invests ¥20 Billion To Increase Capacity
This article was originally published in PharmAsia News
Executive SummaryMajor Japanese generic drug maker Towa Pharmaceutical will invest ¥20 billion to build a new factory in Yamagata Prefecture. To be completed in 2012, the new facility will have an annual production capacity of 7.5 billion tablets and 50 million injections, which is 1.5 times larger than its current site. Towa expects further expansion in the Japanese generic drug market due to the national policy of restraining medical costs.(Click here for more - Japanese language
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.